Selected article for: "human peripheral blood and peripheral blood"
Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA
  • Document date: 2018_6_28
    • ID: tudwns0r_20
    Snippet: The resistance profile for DOT was done in human peripheral blood mononuclear cells (PBMCs) using cloned HIV with known resistance mutations. Against AZT, 3TC and AZT/3TC mutants, DOT retained full activity, even a marginal trend to being more active. Of particular note, DOT was active against the AZT-resistant strain with four mutations (K67N, K70R, T215Y, K219Q), (1.1-fold increase in EC 50 ), and against tenofovir-resistant strain (K65R) (0.5-.....
    Document: The resistance profile for DOT was done in human peripheral blood mononuclear cells (PBMCs) using cloned HIV with known resistance mutations. Against AZT, 3TC and AZT/3TC mutants, DOT retained full activity, even a marginal trend to being more active. Of particular note, DOT was active against the AZT-resistant strain with four mutations (K67N, K70R, T215Y, K219Q), (1.1-fold increase in EC 50 ), and against tenofovir-resistant strain (K65R) (0.5-fold). Although the active moiety, DOTtriphosphate was prepared to investigate its interaction with HIV reverse transcriptase (RT), DOT was not progressed to clinical trials.

    Search related documents:
    Co phrase search for related documents
    • blood mononuclear and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • blood mononuclear and HIV reverse transcriptase: 1
    • blood mononuclear and human peripheral PBMCs blood mononuclear cell: 1, 2, 3, 4, 5
    • blood mononuclear and PBMCs blood mononuclear cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • blood mononuclear and peripheral PBMCs blood mononuclear cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
    • blood mononuclear and reverse transcriptase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • blood mononuclear cell and clinical trial: 1
    • blood mononuclear cell and HIV reverse transcriptase: 1
    • blood mononuclear cell and human peripheral PBMCs blood mononuclear cell: 1, 2, 3, 4, 5
    • blood mononuclear cell and PBMCs blood mononuclear cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
    • blood mononuclear cell and peripheral PBMCs blood mononuclear cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • blood mononuclear cell and reverse transcriptase: 1, 2, 3
    • clinical trial and HIV reverse transcriptase: 1
    • clinical trial and PBMCs blood mononuclear cell: 1
    • clinical trial and peripheral PBMCs blood mononuclear cell: 1
    • clinical trial and reverse transcriptase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • clinical trial and RT HIV reverse transcriptase: 1